DexCom, Inc. (NASDAQ:DXCM – Get Rating) – Stock analysts at Zacks Research boosted their Q1 2025 EPS estimates for shares of DexCom in a note issued to investors on Wednesday, June 21st. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical device company will post earnings per share of $0.36 for the quarter, up from their prior estimate of $0.35. The consensus estimate for DexCom’s current full-year earnings is $1.07 per share.
DexCom (NASDAQ:DXCM – Get Rating) last announced its quarterly earnings results on Thursday, April 27th. The medical device company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.02. DexCom had a return on equity of 18.29% and a net margin of 9.68%. The company had revenue of $7.45 billion during the quarter, compared to analysts’ expectations of $720.52 million. During the same quarter in the previous year, the firm earned $0.08 earnings per share. The business’s quarterly revenue was up 1085.0% compared to the same quarter last year.
DexCom Price Performance
Shares of DexCom stock opened at $126.75 on Monday. The company has a current ratio of 2.02, a quick ratio of 1.82 and a debt-to-equity ratio of 0.54. The firm has a fifty day simple moving average of $121.65 and a 200-day simple moving average of $115.86. The stock has a market capitalization of $49.13 billion, a price-to-earnings ratio of 181.07, a PEG ratio of 2.94 and a beta of 1.15. DexCom has a 1-year low of $72.41 and a 1-year high of $134.14.
Insider Buying and Selling at DexCom
In other DexCom news, SVP Shelly Ramasamy Selvaraj sold 2,115 shares of the firm’s stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $130.00, for a total value of $274,950.00. Following the transaction, the senior vice president now directly owns 50,390 shares of the company’s stock, valued at $6,550,700. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, EVP Sadie Stern sold 393 shares of the business’s stock in a transaction on Friday, June 9th. The shares were sold at an average price of $121.31, for a total value of $47,674.83. Following the sale, the executive vice president now directly owns 82,466 shares of the company’s stock, valued at approximately $10,003,950.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Shelly Ramasamy Selvaraj sold 2,115 shares of the business’s stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $130.00, for a total value of $274,950.00. Following the completion of the sale, the senior vice president now owns 50,390 shares in the company, valued at $6,550,700. The disclosure for this sale can be found here. In the last three months, insiders have sold 71,525 shares of company stock worth $8,656,101. Company insiders own 0.41% of the company’s stock.
Institutional Trading of DexCom
A number of institutional investors have recently made changes to their positions in DXCM. Vanguard Group Inc. raised its position in DexCom by 1.2% during the third quarter. Vanguard Group Inc. now owns 43,682,426 shares of the medical device company’s stock worth $3,518,183,000 after acquiring an additional 511,557 shares in the last quarter. Jennison Associates LLC lifted its stake in DexCom by 32.3% in the 4th quarter. Jennison Associates LLC now owns 9,186,222 shares of the medical device company’s stock valued at $1,040,248,000 after purchasing an additional 2,242,846 shares during the last quarter. Geode Capital Management LLC increased its position in DexCom by 2.1% during the first quarter. Geode Capital Management LLC now owns 8,282,663 shares of the medical device company’s stock worth $960,174,000 after buying an additional 170,796 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of DexCom by 1.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,033,924 shares of the medical device company’s stock worth $456,802,000 after acquiring an additional 44,260 shares during the last quarter. Finally, Norges Bank acquired a new stake in DexCom during the 4th quarter valued at $421,378,000. Institutional investors own 93.97% of the company’s stock.
About DexCom
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices for specific and permitted use cases, including non-medical device applications, medical device data analysis, integrated continuous glucose monitoring systems (iCGM) secondary display alarms, active patient monitoring, and treatment decisions; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.
Featured Articles
- Get a free research report on DexCom from StockNews.com
- MarketBeat Week in Review – 6/19 – 6/23
- CarMax Stock Flying On Earnings Beat, Return Of The Highs?
- Commercial Metals Company Shakes Off The Rust: Confirms Uptrend
- Smith & Wesson, A Timeless Value Play At Decade Lows
- Five stocks we like better than DexCom
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.
